Fortress Biotech Inc. (FBIO)
FBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/0001104659-26-037874-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | FBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001429260 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $63.3M |
| Net income | $6.8M |
| Operating income | -$70.2M |
| Net margin | 10.8% |
| Operating margin | -111.0% |
| Revenue growth | +9.7% |
| Cash | $79.4M |
| Total assets | $185.5M |
| P/E (computed) | 8.5× |
| P/S (computed) | 0.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $196.6M cash; operating cash flow $31.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 33,742,297 (2026-11-10); 31,037,937 a year earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, New York, New York, United States | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $18.7M | -$468K | -$59.3M | $196.6M | $35.0M | $68.5M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $16.0M | $110.4M | $203.9M | $255.8M | $37.5M | $66.2M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $16.1M | -$3.9M | -$12.5M | $79.4M | $54.5M | $63.3M | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $17.6M | $5.8M | -$6.1M | $86.2M | $47.8M | $62.3M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $16.4M | $15.5M | -$27.6M | $74.4M | $50.0M | $59.3M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $13.1M | -$10.6M | -$19.6M | $91.3M | $56.4M | $57.8M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $15.1M | -$6.8M | -$12.9M | $57.3M | $58.0M | $57.7M | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | $14.6M | -$12.9M | -$20.1M | $58.9M | $52.5M | $62.5M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-12-18 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 888 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.6% |
| 1 month | -3.6% |
| 3 months | -36.9% |
| Year to date | -48.6% |
| 1 year | -24.5% |
| From 52-week high | -57.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| FBIOP | Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | $13.86 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BOLD | Boundless Bio Inc. | $2.41 | -3.60% | $56.9M |
| XBIT | XBiotech Inc. | $1.85 | -5.37% | $56.4M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| LFVN | Lifevantage Corporation Common Stock (Delaware) | $4.77 | -4.02% | $60.5M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier